LCD-L36117
Document details
Summary
The new LCD for genetic testing of BCR-ABL negative myeloproliferative disease will impact billing by establishing specific criteria for coverage, thereby influencing reimbursement rates and patient aNew genetic testing LCD affects billing for myeloproliferative disease.
Affected codes
ICD-10-CM
Affected specialty
Hematology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36117&ver=36CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA206769 · Hematology
Argatroban in 0.9% Sodium Chloride (NDA206769) is a new intravenous formulation of the established direct thrombin inhibitor argatroban, approved via a Type 5 submission by Teva Pharmaceuticals. As an
View alertPolicy FDA-BLA761113 · Hematology
Sarclisa (isatuximab) is an injectable CD38-directed cytolytic antibody approved for multiple myeloma, administered via intravenous injection and billing under Medicare Part B. As a hospital or office
View alertPolicy FDA-BLA761166 · Hematology
Besremi (ropeginterferon alfa-2b) is a subcutaneously administered injectable approved for polycythemia vera, supporting a Part B billing pathway as a physician-administered drug. As an orphan drug in
View alertPolicy FDA-NDA209552 · Hematology
The recent FDA approval of Argatroban as an injectable drug suggests it will likely be assigned a J-code for billing under Medicare Part B. Since it is an anticoagulant, providers may receive pass-thr
View alert